Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 79 entries
Sorted by: Best Match Show Resources per page
HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment.

Medical research archives

Ghosh AK, Sarkar A, Mitsuya H.
PMID: 29984302
Med Res Arch. 2017 Apr;5(4). Epub 2017 Apr 15.

The advent of combined active antiretroviral therapy (cART) dramatically improved HIV management and patient care of HIV-infected individuals. This treatment regimen resulted in a significant reduction of HIV/AIDS-related mortality and greatly improved life expectancies of those patients with access...

Cite
Ghosh AK, Sarkar A, Mitsuya H. HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. Med Res Arch. 2017;5(4)
Ghosh, A. K., Sarkar, A., & Mitsuya, H. (2017). HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. Medical research archives, 5(4), .
Ghosh, Arun K, et al. "HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment." Medical research archives vol. 5,4 (2017).
Ghosh AK, Sarkar A, Mitsuya H. HIV-Associated Neurocognitive Disorder (HAND) and the Prospect of Brain-Penetrating Protease Inhibitors for Antiretroviral Treatment. Med Res Arch. 2017 Apr;5(4). Epub 2017 Apr 15. PMID: 29984302; PMCID: PMC6034681.
Copy Download .nbib Format: NLM
ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection.

The Journal of infectious diseases

Kala S, Meteleva K, Serghides L.
PMID: 33880537
J Infect Dis. 2021 Dec 08;224:S631-S641. doi: 10.1093/infdis/jiab166.

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding receptor ACE2 and the spike protein priming protease TMPRSS2 are coexpressed in human placentae. It is unknown whether their expression is altered in the context of HIV infection and antiretroviral...

Cite
Kala S, Meteleva K, Serghides L. ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. J Infect Dis. 2021;224:S631-S641doi: 10.1093/infdis/jiab166.
Kala, S., Meteleva, K., & Serghides, L. (2021). ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. The Journal of infectious diseases, 224S631-S641. https://doi.org/10.1093/infdis/jiab166
Kala, Smriti, et al. "ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection." The Journal of infectious diseases vol. 224 (2021): S631-S641. doi: https://doi.org/10.1093/infdis/jiab166
Kala S, Meteleva K, Serghides L. ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. J Infect Dis. 2021 Dec 08;224:S631-S641. doi: 10.1093/infdis/jiab166. PMID: 33880537; PMCID: PMC8083191.
Copy Download .nbib Format: NLM
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design.

Molecules (Basel, Switzerland)

Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X.
PMID: 34885967
Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385.

SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors present the...

Cite
Yu W, Wu X, Zhao Y, et al. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021;26(23)doi: 10.3390/molecules26237385.
Yu, W., Wu, X., Zhao, Y., Chen, C., Yang, Z., Zhang, X., Ren, J., Wang, Y., Wu, C., Li, C., Chen, R., Wang, X., Zheng, W., Liao, H., & Yuan, X. (2021). Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules (Basel, Switzerland), 26(23), . https://doi.org/10.3390/molecules26237385
Yu, Wei, et al. "Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design." Molecules (Basel, Switzerland) vol. 26,23 (2021). doi: https://doi.org/10.3390/molecules26237385
Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X. Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. Molecules. 2021 Dec 05;26(23). doi: 10.3390/molecules26237385. PMID: 34885967.
Copy Download .nbib Format: NLM
ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection.

The Journal of infectious diseases

Kala S, Meteleva K, Serghides L.
PMID: 33880537
J Infect Dis. 2021 Dec 08;224:S631-S641. doi: 10.1093/infdis/jiab166.

BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding receptor ACE2 and the spike protein priming protease TMPRSS2 are coexpressed in human placentae. It is unknown whether their expression is altered in the context of HIV infection and antiretroviral...

Cite
Kala S, Meteleva K, Serghides L. ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. J Infect Dis. 2021;224:S631-S641doi: 10.1093/infdis/jiab166.
Kala, S., Meteleva, K., & Serghides, L. (2021). ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. The Journal of infectious diseases, 224S631-S641. https://doi.org/10.1093/infdis/jiab166
Kala, Smriti, et al. "ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection." The Journal of infectious diseases vol. 224 (2021): S631-S641. doi: https://doi.org/10.1093/infdis/jiab166
Kala S, Meteleva K, Serghides L. ACE2, TMPRSS2, and L-SIGN Expression in Placentae From HIV-Positive Pregnancies Exposed to Antiretroviral Therapy-Implications for SARS-CoV-2 Placental Infection. J Infect Dis. 2021 Dec 08;224:S631-S641. doi: 10.1093/infdis/jiab166. PMID: 33880537; PMCID: PMC8083191.
Copy Download .nbib Format: NLM
Regulatory issues in developing new HIV protease inhibitors: risks and benefits.

Current opinion in HIV and AIDS

Struble KA, Chan-Tack KM, Soon GG.
PMID: 19373041
Curr Opin HIV AIDS. 2008 Nov;3(6):676-80. doi: 10.1097/COH.0b013e3283136cb1.

PURPOSE OF REVIEW: To provide a regulatory perspective on developing new HIV protease inhibitors. The present review highlights the risks and benefits of certain design aspects for studies in treatment-naïve and treatment-experienced patients, including timing of studies, study design...

Cite
Struble KA, Chan-Tack KM, Soon GG. Regulatory issues in developing new HIV protease inhibitors: risks and benefits. Curr Opin HIV AIDS. 2008;3(6):676-80doi: 10.1097/COH.0b013e3283136cb1.
Struble, K. A., Chan-Tack, K. M., & Soon, G. G. (2008). Regulatory issues in developing new HIV protease inhibitors: risks and benefits. Current opinion in HIV and AIDS, 3(6), 676-80. https://doi.org/10.1097/COH.0b013e3283136cb1
Struble, Kimberly A, et al. "Regulatory issues in developing new HIV protease inhibitors: risks and benefits." Current opinion in HIV and AIDS vol. 3,6 (2008): 676-80. doi: https://doi.org/10.1097/COH.0b013e3283136cb1
Struble KA, Chan-Tack KM, Soon GG. Regulatory issues in developing new HIV protease inhibitors: risks and benefits. Curr Opin HIV AIDS. 2008 Nov;3(6):676-80. doi: 10.1097/COH.0b013e3283136cb1. PMID: 19373041.
Copy Download .nbib Format: NLM
Toxicity of HIV protease inhibitors: clinical considerations.

Current opinion in HIV and AIDS

Boesecke C, Cooper DA.
PMID: 19373038
Curr Opin HIV AIDS. 2008 Nov;3(6):653-9. doi: 10.1097/COH.0b013e328312c392.

PURPOSE OF REVIEW: To review recent studies reporting toxicity, adverse events, side effects, and drug-drug interactions related to the use of HIV protease inhibitors, with particular focus on possible clinical implications.RECENT FINDINGS: Toxicity-associated adverse events still remain a major...

Cite
Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS. 2008;3(6):653-9doi: 10.1097/COH.0b013e328312c392.
Boesecke, C., & Cooper, D. A. (2008). Toxicity of HIV protease inhibitors: clinical considerations. Current opinion in HIV and AIDS, 3(6), 653-9. https://doi.org/10.1097/COH.0b013e328312c392
Boesecke, Christoph, and Cooper, David A. "Toxicity of HIV protease inhibitors: clinical considerations." Current opinion in HIV and AIDS vol. 3,6 (2008): 653-9. doi: https://doi.org/10.1097/COH.0b013e328312c392
Boesecke C, Cooper DA. Toxicity of HIV protease inhibitors: clinical considerations. Curr Opin HIV AIDS. 2008 Nov;3(6):653-9. doi: 10.1097/COH.0b013e328312c392. PMID: 19373038.
Copy Download .nbib Format: NLM
Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources.

Microorganisms

Razali R, Asis H, Budiman C.
PMID: 34946083
Microorganisms. 2021 Nov 30;9(12). doi: 10.3390/microorganisms9122481.

The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is considered the greatest challenge to the global health community of the century as it continues to expand. This has prompted immediate urgency to discover promising drug...

Cite
Razali R, Asis H, Budiman C. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms. 2021;9(12)doi: 10.3390/microorganisms9122481.
Razali, R., Asis, H., & Budiman, C. (2021). Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms, 9(12), . https://doi.org/10.3390/microorganisms9122481
Razali, Rafida, et al. "Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources." Microorganisms vol. 9,12 (2021). doi: https://doi.org/10.3390/microorganisms9122481
Razali R, Asis H, Budiman C. Structure-Function Characteristics of SARS-CoV-2 Proteases and Their Potential Inhibitors from Microbial Sources. Microorganisms. 2021 Nov 30;9(12). doi: 10.3390/microorganisms9122481. PMID: 34946083; PMCID: PMC8706127.
Copy Download .nbib Format: NLM
Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from .

Journal of fungi (Basel, Switzerland)

Santos ALS, Braga-Silva LA, Gonçalves DS, Ramos LS, Oliveira SSC, Souza LOP, Oliveira VS, Lins RD, Pinto MR, Muñoz JE, Taborda CP, Branquinha MH.
PMID: 34071195
J Fungi (Basel). 2021 May 28;7(6). doi: 10.3390/jof7060424.

The repurposing strategy was applied herein to evaluate the effects of lopinavir, an aspartic protease inhibitor currently used in the treatment of HIV-infected individuals, on the globally widespread opportunistic human fungal pathogen

Cite
Santos ALS, Braga-Silva LA, Gonçalves DS, et al. Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from . J Fungi (Basel). 2021;7(6)doi: 10.3390/jof7060424.
Santos, A. L. S., Braga-Silva, L. A., Gonçalves, D. S., Ramos, L. S., Oliveira, S. S. C., Souza, L. O. P., Oliveira, V. S., Lins, R. D., Pinto, M. R., Muñoz, J. E., Taborda, C. P., & Branquinha, M. H. (2021). Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from . Journal of fungi (Basel, Switzerland), 7(6), . https://doi.org/10.3390/jof7060424
Santos, André L S, et al. "Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from ." Journal of fungi (Basel, Switzerland) vol. 7,6 (2021). doi: https://doi.org/10.3390/jof7060424
Santos ALS, Braga-Silva LA, Gonçalves DS, Ramos LS, Oliveira SSC, Souza LOP, Oliveira VS, Lins RD, Pinto MR, Muñoz JE, Taborda CP, Branquinha MH. Repositioning Lopinavir, an HIV Protease Inhibitor, as a Promising Antifungal Drug: Lessons Learned from . J Fungi (Basel). 2021 May 28;7(6). doi: 10.3390/jof7060424. PMID: 34071195; PMCID: PMC8229492.
Copy Download .nbib Format: NLM
miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir.

Frontiers in pharmacology

Bresciani E, Saletti C, Squillace N, Rizzi L, Molteni L, Meanti R, Omeljaniuk RJ, Biagini G, Gori A, Locatelli V, Torsello A.
PMID: 31133852
Front Pharmacol. 2019 Apr 30;10:461. doi: 10.3389/fphar.2019.00461. eCollection 2019.

No abstract available.

Cite
Bresciani E, Saletti C, Squillace N, et al. miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. Front Pharmacol. 2019;10:461doi: 10.3389/fphar.2019.00461.
Bresciani, E., Saletti, C., Squillace, N., Rizzi, L., Molteni, L., Meanti, R., Omeljaniuk, R. J., Biagini, G., Gori, A., Locatelli, V., & Torsello, A. (2019). miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. Frontiers in pharmacology, 10461. https://doi.org/10.3389/fphar.2019.00461
Bresciani, Elena, et al. "miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir." Frontiers in pharmacology vol. 10 (2019): 461. doi: https://doi.org/10.3389/fphar.2019.00461
Bresciani E, Saletti C, Squillace N, Rizzi L, Molteni L, Meanti R, Omeljaniuk RJ, Biagini G, Gori A, Locatelli V, Torsello A. miRNA-218 Targets Lipin-1 and Glucose Transporter Type 4 Genes in 3T3-L1 Cells Treated With Lopinavir/Ritonavir. Front Pharmacol. 2019 Apr 30;10:461. doi: 10.3389/fphar.2019.00461. eCollection 2019. PMID: 31133852; PMCID: PMC6524698.
Copy Download .nbib Format: NLM
Amino Acid and Peptide-Based Antiviral Agents.

ChemMedChem

Skwarecki AS, Nowak MG, Milewska MJ.
PMID: 34254457
ChemMedChem. 2021 Oct 15;16(20):3106-3135. doi: 10.1002/cmdc.202100397. Epub 2021 Aug 03.

A significant number of antiviral agents used in clinical practice are amino acids, short peptides, or peptidomimetics. Among them, several HIV protease inhibitors (e. g. lopinavir, atazanavir), HCV protease inhibitors (e. g. grazoprevir, glecaprevir), and HCV NS5A protein inhibitors...

Cite
Skwarecki AS, Nowak MG, Milewska MJ. Amino Acid and Peptide-Based Antiviral Agents. ChemMedChem. 2021;16(20):3106-3135doi: 10.1002/cmdc.202100397.
Skwarecki, A. S., Nowak, M. G., & Milewska, M. J. (2021). Amino Acid and Peptide-Based Antiviral Agents. ChemMedChem, 16(20), 3106-3135. https://doi.org/10.1002/cmdc.202100397
Skwarecki, Andrzej S, et al. "Amino Acid and Peptide-Based Antiviral Agents." ChemMedChem vol. 16,20 (2021): 3106-3135. doi: https://doi.org/10.1002/cmdc.202100397
Skwarecki AS, Nowak MG, Milewska MJ. Amino Acid and Peptide-Based Antiviral Agents. ChemMedChem. 2021 Oct 15;16(20):3106-3135. doi: 10.1002/cmdc.202100397. Epub 2021 Aug 03. PMID: 34254457.
Copy Download .nbib Format: NLM
re- and si-Face-Selective Nitroaldol Reactions Catalyzed by a Rigid Chiral Quaternary Ammonium Salt: A Highly Stereoselective Synthesis of the HIV Protease Inhibitor Amprenavir (Vertex 478).

Angewandte Chemie (International ed. in English)

Corey EJ, Zhang FY.
PMID: 34182655
Angew Chem Int Ed Engl. 1999 Jul 12;38(13):1931-1934. doi: 10.1002/(SICI)1521-3773(19990712)38:13/14<1931::AID-ANIE1931>3.0.CO;2-4.

Either amprenavir (1) or its C(2) diastereomer can be synthesized in a simple way by the use of a nitroaldol reaction carried out in the presence of one or the other of the two ammonium ions 2. The 1,3-diamino-2-hydroxypropyl...

Cite
Corey EJ, Zhang FY. re- and si-Face-Selective Nitroaldol Reactions Catalyzed by a Rigid Chiral Quaternary Ammonium Salt: A Highly Stereoselective Synthesis of the HIV Protease Inhibitor Amprenavir (Vertex 478). Angew Chem Int Ed Engl. 1999;38(13):1931-1934doi: 10.1002/(SICI)1521-3773(19990712)38:13/14<1931::AID-ANIE1931>3.0.CO;2-4.
Corey, E. J., & Zhang, F. Y. (1999). re- and si-Face-Selective Nitroaldol Reactions Catalyzed by a Rigid Chiral Quaternary Ammonium Salt: A Highly Stereoselective Synthesis of the HIV Protease Inhibitor Amprenavir (Vertex 478). Angewandte Chemie (International ed. in English), 38(13), 1931-1934. https://doi.org/10.1002/(SICI)1521-3773(19990712)38:13/14<1931::AID-ANIE1931>3.0.CO;2-4
Corey, E J, and Zhang, Fu-Yao. "re- and si-Face-Selective Nitroaldol Reactions Catalyzed by a Rigid Chiral Quaternary Ammonium Salt: A Highly Stereoselective Synthesis of the HIV Protease Inhibitor Amprenavir (Vertex 478)." Angewandte Chemie (International ed. in English) vol. 38,13 (1999): 1931-1934. doi: https://doi.org/10.1002/(SICI)1521-3773(19990712)38:13/14<1931::AID-ANIE1931>3.0.CO;2-4
Corey EJ, Zhang FY. re- and si-Face-Selective Nitroaldol Reactions Catalyzed by a Rigid Chiral Quaternary Ammonium Salt: A Highly Stereoselective Synthesis of the HIV Protease Inhibitor Amprenavir (Vertex 478). Angew Chem Int Ed Engl. 1999 Jul 12;38(13):1931-1934. doi: 10.1002/(SICI)1521-3773(19990712)38:13/14<1931::AID-ANIE1931>3.0.CO;2-4. PMID: 34182655.
Copy Download .nbib Format: NLM
Current Potential Therapeutic Approaches against SARS-CoV-2: A Review.

Biomedicines

Yadav DK, Singh DD, Han I, Kumar Y, Choi EH.
PMID: 34829850
Biomedicines. 2021 Nov 04;9(11). doi: 10.3390/biomedicines9111620.

The ongoing SARS-CoV-2 pandemic is a serious threat to public health worldwide and, to date, no effective treatment is available. Thus, we herein review the pharmaceutical approaches to SARS-CoV-2 infection treatment. Numerous candidate medicines that can prevent SARS-CoV-2 infection...

Cite
Yadav DK, Singh DD, Han I, et al. Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. Biomedicines. 2021;9(11)doi: 10.3390/biomedicines9111620.
Yadav, D. K., Singh, D. D., Han, I., Kumar, Y., & Choi, E. H. (2021). Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. Biomedicines, 9(11), . https://doi.org/10.3390/biomedicines9111620
Yadav, Dharmendra Kumar, et al. "Current Potential Therapeutic Approaches against SARS-CoV-2: A Review." Biomedicines vol. 9,11 (2021). doi: https://doi.org/10.3390/biomedicines9111620
Yadav DK, Singh DD, Han I, Kumar Y, Choi EH. Current Potential Therapeutic Approaches against SARS-CoV-2: A Review. Biomedicines. 2021 Nov 04;9(11). doi: 10.3390/biomedicines9111620. PMID: 34829850; PMCID: PMC8615922.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 79 entries